Brain Cancer Patients Display Decreasing Tumor Biomarkers After Treatment with Novel Immunotherapy in AIVITA Biomedical’s Phase 2 Clinical Trial

Brain Cancer Patients Display Decreasing Tumor Biomarkers After Treatment with Novel Immunotherapy in AIVITA Biomedical’s Phase 2 Clinical Trial

AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today updated clinical data from its ongoing glioblastoma Phase 2 clinical trial, investigating AIVITA’s platform immunotherapy...

Read more
FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs

FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs

The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...

Read more
China News Weekly 123 – China January-July FDI up 7.3% Year on Year in  Yuan Terms

China News Weekly 123 – China January-July FDI up 7.3% Year on Year in Yuan Terms

Click here to find more details This is NAI’s new China News Weekly. We will be covering the latest Chinese foreign investment trends every week. To continue to receive our China News Weekly, please click the button below to subscribe.

Read more
Aslan Presents Progress Update on its Three Clinical Candidates

Aslan Presents Progress Update on its Three Clinical Candidates

Aslan Pharma of Singapore provided an update on the progress of its three clinical-stage oncology and immunology candidates: • The company signed up K-MASTER to run a 400 patient South Korean Phase Ib/II trial of its lead drug, varlitinib, in...

Read more
Chipscreen Bio Climbs 367% on First Trading Day following Shanghai IPO

Chipscreen Bio Climbs 367% on First Trading Day following Shanghai IPO

China’s Chipscreen Bio gained a stunning 367% in its first trading session following its IPO on the Shanghai STAR exchange, giving the company a market cap of $4.2 billion, When the first 25 STAR Board IPOs hit the market last month, the...

Read more
Ascletis Opens Clinical Development Shanghai Center

Ascletis Opens Clinical Development Shanghai Center

Ascletis Pharma Inc.(1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today the opening of its...

Read more
Ligand Partner CASI Pharmaceuticals Launches EVOMELA® in China

Ligand Partner CASI Pharmaceuticals Launches EVOMELA® in China

Ligand Pharmaceuticals Inc. (NASDAQ: LGND) partner CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and accelerating the launch of innovative therapeutics and pharmaceutical products in China, the...

Read more
Shanghai’s Stemirna Raises $14 Million for RNA Drug Development

Shanghai’s Stemirna Raises $14 Million for RNA Drug Development

Stemirna Therapeutics, a Shanghai RNA biopharma, raised nearly $14 million in a Series A financing. Founded in 2016 by a group of returning PhDs from MD Anderson Cancer Center in Houston, the company uses its proprietary Core Shell Structure...

Read more
Vapo Health Completes Series A Round for Medical Device Business

Vapo Health Completes Series A Round for Medical Device Business

Vapo Health, a China medical device company specializing in nebulizers, completed a Series A financing led by CCB International. Although the specific amount was not disclosed, it was reported to be in the “millions of dollars” range...

Read more
Endologix Announces Exclusive Distributor Agreement with Boston Scientific for the Chinese Market

Endologix Announces Exclusive Distributor Agreement with Boston Scientific for the Chinese Market

Endologix Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced an agreement naming Boston Scientific Corporation (NYSE: BSX) the exclusive distributor for Endologix products in China. The...

Read more
AstraZeneca’s Tagrisso helps lung cancer patients live longer: study

AstraZeneca’s Tagrisso helps lung cancer patients live longer: study

AstraZeneca Plc said on Friday a late-stage study showed its top-selling drug, Tagrisso, had significantly helped patients with a type of lung cancer live longer without the disease worsening. The British drugmaker announced overall positive...

Read more
Kangpu Bio-Pharma Completes $14 Million Pre-B Round for Immuno-Modulators

Kangpu Bio-Pharma Completes $14 Million Pre-B Round for Immuno-Modulators

Kangpu Bio-Pharma, a Shanghai clinical stage company, completed a $14 million Pre-B financing. Headquartered in Zhangjiang Hi-Tech Park, Kangpu is focused on developing small molecule drugs targeting immuno-modulating sites to develop treatments...

Read more
Do NOT follow this link or you will be banned from the site!